Halozyme therapeutics to Present at the Roth Capital Partners 19th Annual OC Conference

SAN DIEGO, Feb. 13 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Amex: HTI), a biopharmaceutical company developing and commercializing recombinant human enzymes, today announced that it will present at the Roth Capital Partners 19th Annual OC Conference to be held at The Ritz Carlton in Laguna Niguel, Calif., on February 19-22, 2007.

Jonathan Lim, MD, Halozyme's President and Chief Executive Officer, will present on Wednesday, February 21, 2007 at 5:00 p.m. Pacific time (8:00 p.m. Eastern time) and will discuss the Company's strategic initiatives, product pipeline and market opportunities.

Interested parties can access a live audio webcast and accompanying slide presentation via the Internet by visiting the Investor Relations section of the Company's Web site at www.halozyme.com. An archived presentation will be available on the Web site for 30 days.

About Halozyme Therapeutics, Inc.

Halozyme is a biopharmaceutical company developing and commercializing recombinant human enzymes for the drug delivery, palliative care, oncology, and infertility markets. The company's portfolio of products is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company's Enhanze(TM) Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. Its first partnership is with Roche to apply Enhanze Technology to Roche's biological therapeutic compounds for 13 targets. In addition, the company has received FDA approval for two products: Cumulase(R) and Hylenex, for use as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids. The Company also has a number of different enzymes in its portfolio that are targeting significant areas of unmet need.

    Halozyme Contact                     Investor Relations Contact
    David A. Ramsay                      Don Markley
    Chief Financial Officer              Lippert/Heilshorn & Associates
    (858) 794-8881                       (310) 691-7100
    [email protected]                 [email protected]

SOURCE Halozyme Therapeutics, Inc.
02/13/2007
CONTACT: David A. Ramsay, Chief Financial Officer of Halozyme
Therapeutics, Inc., +1-858-794-8881, [email protected]; or Investor
Relations, Don Markley of Lippert/Heilshorn & Associates, +1-310-691-7100,
[email protected], for Halozyme Therapeutics, Inc.
Web site: http://www.halozyme.com
(HTI)